American Capital Advisory’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$334K Buy
921
+36
+4% +$12.3K 0.12% 85
2026
Q1
$311K Buy
885
+9
+1% +$3.21K 0.13% 85
2025
Q4
$287K Buy
876
+6
+0.7% +$1.9K 0.12% 86
2025
Q3
$246K Sell
870
-5
-0.6% -$1.45K 0.11% 90
2025
Q2
$244K Buy
875
+7
+0.8% +$1.98K 0.12% 89
2025
Q1
$270K Buy
868
+55
+7% +$16.2K 0.15% 88
2024
Q4
$212K Hold
813
0.12% 92
2024
Q3
$262K Hold
813
0.15% 84
2024
Q2
$234K Hold
813
0.17% 80
2024
Q1
$197K Hold
813
0.17% 84
2023
Q4
$234K Buy
+813
New +$222K 0.17% 80

Other funds holding AMGN

American Capital Advisory's AMGN Position: Q2 2026 in Review

American Capital Advisory increased its Amgen (AMGN) stake by 4.1% in Q2 2026, buying an estimated $12.3K and bringing the position to 921 shares worth $334K. The position accounts for 0.12% of the portfolio, ranked #85.

American Capital Advisory first reported a position in AMGN in Q4 2023 and has held it in 11 quarters since. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • American Capital Advisory held 921 shares of Amgen worth $334K as of Q2 2026.
  • American Capital Advisory bought 36 Amgen shares in Q2 2026, an estimated $12.3K.
  • Amgen made up 0.12% of American Capital Advisory's portfolio in Q2 2026, its #85 holding.
  • American Capital Advisory first reported a position in Amgen in Q4 2023 and has held it in 11 quarters since.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.